TANGO THERAPEUTICS, INC. financials

TNGX CIK 0001819133

Source: EDGAR filings · Built 2026-06-02T04:11:44Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Free Cash Flow -139.93M -132.25M -119.51M -116.77M -61.36M 68.97M
EBITDA -109.01M -143.10M -111.76M -109.46M -57.29M -51.48M
Working Capital 332.08M 228.17M 300.60M 319.73M 451.65M 152.72M
Net Debt -78.71M -33.04M -29.89M -18.84M -141.24M -20.50M
Operating Margin -178.39% -346.09% -312.57% -446.79% -157.09% -681.82%
Net Margin -162.85% -309.73% -278.54% -435.14% -157.21% -678.84%
Return on Equity (ROE) -29.35% -65.31% -40.20% -43.36% -16.89% -134.64%
Return on Assets (ROA) -25.48% -41.17% -25.27% -24.78% -11.64% -25.08%
Current Ratio 16.32× 6.98× 7.54× 6.76× 12.10× 4.73×
Debt-to-Equity 0.10× 0.18× 0.14× 0.16× 0.00× 0.20×
Effective Tax Rate -0.00% -0.16% -0.13% -0.05% -0.50% 0.00%
Cash Conversion Ratio 1.37× 1.01× 1.16× 1.01× 1.02× -1.35×
Accruals Ratio 0.09× 0.00× 0.04× 0.00× 0.00× -0.59×
SBC % of Revenue 42.37% 68.69% 52.23% 57.24% 21.15% 23.04%
CapEx Coverage -132.52× -174.40× -77.31× -14.18× -32.40× 63.36×
Free Cash Flow Per Share $-1.20 $-1.21 $-1.26 $-1.33 $-0.99 $2.16

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
P/FCF 5.30×
FCF Yield 18.88%
P/S 19.31× 7.91× 27.70× 25.72× 25.87× 60.33×
P/B 3.48× 1.67× 4.00× 2.56× 2.78× 11.97×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Revenues 62.38M 42.07M 36.53M 24.86M 37.04M 7.66M
Research and Development Expense 132.16M 143.92M 115.20M 105.91M 77.64M 49.99M
Operating Expenses 173.67M 187.66M 150.70M 135.93M 95.23M 59.86M
Operating Income (Loss) -111.29M -145.59M -114.17M -111.07M -58.19M -52.20M
Income Tax Expense (Benefit) 4.00K 208.00K 134.00K 54.00K 292.00K 0
Net Income (Loss) Attributable to Parent -101.59M -130.30M -101.74M -108.18M -58.23M -51.97M
Earnings Per Share, Basic $-0.87 $-1.19 $-1.08 $-1.23 $-0.94
Weighted Average Number of Shares Outstanding, Basic 116.17M 109.23M 94.57M 87.82M 62.11M
Earnings Per Share, Diluted $-0.87 $-1.19 $-1.08 $-1.23 $-0.94
Weighted Average Number of Shares Outstanding, Diluted 116.17M 109.23M 94.57M 87.82M 62.11M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Cash and Cash Equivalents, at Carrying Value 112.28M 69.53M 66.39M 59.97M 142.75M 28.38M
Assets, Current 353.76M 266.34M 346.54M 375.27M 492.34M 193.63M
Assets 398.69M 316.49M 402.57M 436.47M 500.15M 207.25M
Liabilities, Current 21.68M 38.17M 45.94M 55.55M 40.69M 40.92M
Liabilities 52.51M 116.97M 149.46M 186.99M 155.41M 168.65M
Stockholders' Equity Attributable to Parent 346.18M 199.52M 253.11M 249.48M 344.75M 38.60M
Common Stock, Shares, Outstanding 135.94M 107.73M 102.20M 88.18M 87.60M 40.37M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Net Cash Provided by (Used in) Operating Activities -138.89M -131.50M -117.98M -109.08M -59.53M 70.07M
Payments to Acquire Property, Plant, and Equipment 1.05M 754.00K 1.53M 7.69M 1.84M 1.11M
Net Cash Provided by (Used in) Investing Activities -40.87M 86.13M 41.43M 26.40M -183.43M -145.47M
Net Cash Provided by (Used in) Financing Activities 222.50M 47.66M 82.41M 1.61M 357.32M 80.88M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (TNGX CIK 0001819133), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

CLOV

CLOVER HEALTH INVESTMENTS, CORP. /DE

LNC

LINCOLN NATIONAL CORPORATION

TARA

Protara Therapeutics, Inc.